

TARGETED THERAPIES IN ONCOLOGY

MOLECULAR PROFILING

New era for Precision Medicine

Precision medicine is fundamentally changing the health care globally. To treat a particular disease like cancer, this approach uses the individual's genomic information to personalize and tailor targeted treatments for maximum effectiveness, and minimal toxicity to that individual patient, unlike the traditional "one size fits all" approach.

Hence, translational genomics approaches from bench to bedside is shaping the promise of P4 medicine [personalized, predictive, preventive, and participatory].

Date : 7th July 2021

Time : 6:00 PM

Join Live on :




Dr Anuradha Choughule

(PhD)

Professor & Faculty Scientist
Consultant Molecular Laboratory

Dr Anuradha Choughule has 35+ years' experience as a Professor and Faculty Scientist at the Homi Bhabha National Institute (HBNI), in Medical Oncology at Tata Memorial Hospital (TMH), Mumbai. TMH is the top-most Cancer Research & Treatment Institute in Asia and treats over 70,000+ new cancer patients every year. She has 65+ Peer reviewed Publications in International and National Journals. She has also 100+ presentations on International and National Platforms. Her genomics advice is sought on several local, national and international forums and at several weekly "Molecular Tumor Boards" with national and international Oncologists. Her extensive work of molecular Profiling in Lung Cancer is highly recognized at International Level. She is also a Pioneer in establishing Liquid Biopsy testing in Lung Cancer at Tata Memorial Hospital. As a NABL ASSESSOR for Molecular testing, she has evaluated 50+ Molecular diagnostic Laboratories in India.





TARGETED THERAPIES IN ONCOLOGY

LIQUID BIOPSY

Non-invasive & Cheaper Alternative
To Tissue Biopsy In Solid Tumors

Heterogeneity of Tumor genome and continuous polyclonal expansion, can complicate diagnosis, treatment and the assessment of acquired resistance. Tumor tissues are limited both spatially to the region biopsied, and to the state of tumor at the time of biopsy. Tissue biopsies lose the opportunity to take serial samples for longitudinal monitoring of tumor genomic evolution in real time.

Liquid biopsy, is emerging as a novel method for cancer targeted therapy by identification of specific druggable genetic alterations in bloodstream and other bio-fluids. The amount of circulating cell free DNA (cfDNA) is influenced by tumor progression, turnover of tumor, tumor size, as well as clearance, degradation, and filtering by the blood and lymphatic circulation. Thus, this technology is promising for point-of-care testing to be taken to monitor dynamic changes in the molecular landscape during tumor progression or drug treatment.

Date : 8th July 2021

Time : 6:00 PM

Join Live on :



Dr Anuradha Choughule

(PhD)

Professor & Faculty Scientist
Consultant Molecular Laboratory

Dr Anuradha Choughule has 35+ years' experience as a Professor and Faculty Scientist at the Homi Bhabha National Institute (HBNI), in Medical Oncology at Tata Memorial Hospital (TMH), Mumbai. TMH is the top-most Cancer Research & Treatment Institute in Asia and treats over 70,000+ new cancer patients every year. She has 65+ Peer reviewed Publications in International and National Journals. She has also 100+ presentations on International and National Platforms. Her genomics advice is sought on several local, national and international forums and at several weekly "Molecular Tumor Boards" with national and international Oncologists. Her extensive work of molecular Profiling in Lung Cancer is highly recognized at International Level. She is also a Pioneer in establishing Liquid Biopsy testing in Lung Cancer at Tata Memorial Hospital. As a NABL ASSESSOR for Molecular testing, she has evaluated 50+ Molecular diagnostic Laboratories in India.

